Nrf2 inactivation enhances placental angiogenesis in a preeclampsia mouse model and improves maternal and fetal outcomes.

dc.contributor.author

Nezu, Masahiro

dc.contributor.author

Souma, Tomokazu

dc.contributor.author

Yu, Lei

dc.contributor.author

Sekine, Hiroki

dc.contributor.author

Takahashi, Nobuyuki

dc.contributor.author

Wei, Andrew Zu-Sern

dc.contributor.author

Ito, Sadayoshi

dc.contributor.author

Fukamizu, Akiyoshi

dc.contributor.author

Zsengeller, Zsuzsanna K

dc.contributor.author

Nakamura, Tomohiro

dc.contributor.author

Hozawa, Atsushi

dc.contributor.author

Karumanchi, S Ananth

dc.contributor.author

Suzuki, Norio

dc.contributor.author

Yamamoto, Masayuki

dc.date.accessioned

2018-05-01T15:19:32Z

dc.date.available

2018-05-01T15:19:32Z

dc.date.issued

2017-05-16

dc.date.updated

2018-05-01T15:19:31Z

dc.description.abstract

Placental activation of the renin-angiotensin system (RAS) plays a key role in the pathogenesis of preeclampsia. Reactive oxygen species (ROS) are thought to affect placental angiogenesis, which is critical for preventing preeclampsia pathology. We examined the role of ROS in preeclampsia by genetically modifying the Keap1-Nrf2 pathway, a cellular antioxidant defense system, in a mouse model of RAS-induced preeclampsia. Nrf2 deficiency would be expected to impair cellular antioxidant responses; however, Nrf2 deficiency in preeclamptic mice improved maternal and fetal survival, ameliorated intra-uterine growth retardation, and augmented oxidative DNA damage. Furthermore, the placentas of Nrf2-deficient mice had increased endothelial cell proliferation with dense vascular networks. In contrast, the placentas of preeclamptic mice with overactive Nrf2 showed repressed angiogenesis, which was associated with decreased expression of genes encoding angiogenic chemokines and cytokines. Our findings support the notion that ROS-mediated signaling is essential for maintaining placental angiogenesis in preeclampsia and may provide mechanistic insight into the negative results of clinical trials for antioxidants in preeclampsia.

dc.identifier.issn

1945-0877

dc.identifier.issn

1937-9145

dc.identifier.uri

https://hdl.handle.net/10161/16649

dc.language

eng

dc.publisher

American Association for the Advancement of Science (AAAS)

dc.relation.ispartof

Science signaling

dc.relation.isversionof

10.1126/scisignal.aam5711

dc.subject

Placenta

dc.subject

Animals

dc.subject

Mice, Transgenic

dc.subject

Humans

dc.subject

Mice

dc.subject

Fetal Growth Retardation

dc.subject

Pre-Eclampsia

dc.subject

DNA Damage

dc.subject

Disease Models, Animal

dc.subject

Reactive Oxygen Species

dc.subject

Cytokines

dc.subject

Antioxidants

dc.subject

Pregnancy Outcome

dc.subject

Gene Expression

dc.subject

Oxidative Stress

dc.subject

Fetal Development

dc.subject

Pregnancy

dc.subject

Neovascularization, Physiologic

dc.subject

Female

dc.subject

NF-E2-Related Factor 2

dc.title

Nrf2 inactivation enhances placental angiogenesis in a preeclampsia mouse model and improves maternal and fetal outcomes.

dc.type

Journal article

duke.contributor.orcid

Souma, Tomokazu|0000-0002-3285-8613

pubs.issue

479

pubs.organisational-group

School of Medicine

pubs.organisational-group

Duke

pubs.organisational-group

Medicine, Nephrology

pubs.organisational-group

Medicine

pubs.organisational-group

Clinical Science Departments

pubs.publication-status

Published

pubs.volume

10

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
eaam5711.full.pdf
Size:
6.13 MB
Format:
Adobe Portable Document Format
Description:
Published version